Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Takeda is supporting the BLA with data from the pivotal VISIBLE 2 Phase III trial, in which 409 adult patients experienced a clinical responsedefined as a decrease of 70 points or more in Crohns Disease Activity Index (CDAI) score from baselinefollowing two doses of open-label IV Entyvio
So let's play a little game
Can adoption reach a critical mass
We do not dispense or prescribe medications
US$ 20.79
US$ 23.24
US$ 27.24
